Please assess the completion status of the following clinical trial:

Trial Title: Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed primary acute myeloid leukemia (AML)~  * At least 20% bone marrow blasts~ * Meets the customary FAB criteria for AML~    * Patients with cytopenias and bone marrow blasts who do not meet the FAB criteria are eligible provided they have a karyotypic abnormality characteristic of de novo AML (e.g., t\[8;21\], inv16, or t\[16;16\]) OR they have the unequivocal presence of megakaryoblasts~ * Isolated granulocytic sarcoma (myeloblastoma) allowed regardless of the results outlined above~* Previously untreated disease~* No promyelocytic leukemia (FAB M3)~* No documented myelodysplastic syndromes (preleukemia) (e.g., chronic myelomonocytic leukemia, refractory anemia \[RA\], RA with excess blasts, or RA with ringed sideroblasts)~* No juvenile myelomonocytic leukemia~* No Fanconi's anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome~* No Down syndrome~PATIENT CHARACTERISTICS:~Age~* 1 month to 21 years\* NOTE: \*Children under 1 month of age who have progressive disease are allowed~Performance status~* Karnofsky 50-100% (over 16 years of age) OR~* Lansky 50-100% (ages 1 to 16)\* NOTE: Children under 1 year of age do not require a performance status~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* No inadequate liver function~Renal~* No inadequate renal function~* No hyperuricemia (greater than 8.0 mg/dL)~* Creatinine clearance or radioisotope glomerular filtration rate (GFR) at least 70 mL/min OR an equivalent normal GFR OR~* Creatinine no greater than 1.5 times normal~Cardiovascular~* Shortening fraction at least 27% by echocardiogram OR~* Ejection fraction at least 50% by MUGA~Pulmonary~* No proven or suspected pneumonia~Other~* Not pregnant or nursing~* No proven or suspected sepsis or meningitis~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy except intrathecal cytarabine administered that was administered at diagnosis~Endocrine therapy~* Prior topical and inhalation steroids allowed~* No concurrent steroids as antiemetics~Radiotherapy~* No prior radiotherapy~Surgery~* Not specified~Other~* No prior antileukemic therapy~* No concurrent pressor agent or ventilatory support unless approved by the study chair~* No concurrent participation in another COG therapeutic study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).